of patients, %)
EGFR mutation Positive this website Negative pTyr1068 + – p + – p Total 84 8 – 80 33 – TKI therapy 78 8 – 69 31 – ORR(CR + PR) 53.8(42/78) 12.5(1/8) 0.029 23.2(16/69) 3.2(1/31) 0.01 DCR CR + PR + SD 85.9(67/78) 62.5(5/8) 0.118 69.6(48/69) 35.5(11/31) 0.001 PD 14.1(11/78) 37.5(3/8) 30.4(21/69) 64.5(20/31) PFS(months) Median 9.1 4.6 0.224 3.6 1.2 <0.001 95% CI 6.25-11.94 0.00-11.53 1.03-6.30 1.00-1.46 Abbreviations: EGFR, epidermal growth factor receptor; pTyr, phophorylated tyrosine; CR, complete remission; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease click here control rate; PFS, progression-free survival. Of 194 patients who received EGFR-TKIs therapy, 54 (27%) patients received EGFR-TKIs as first-line therapy and 140 (73%) patients as second- or more-line. 60 patients (31%) experienced PR, 71(37%) patients
got SD and 63(32%) had PD. No CR was observed. The ORR and DCR of EGFR-TKIs treatment were both higher in patients with EGFR mutations than those without EGFR mutation; ORR was 50.0% (43/89) vs. 17.0% (17/105) P < 0.001, DCR was 83.7% (72/89) vs. 59.0% (59/105) P < 0.001. In a multivariate analysis involving tumor histology, smoking status, sex, and tumor stage, EGFR mutation was an independent factor for tumor response (OR 0.18, 95% CI 0.09 to 0.38, P < 0.001) (Table 1). PFS was significantly different between patients with EGFR mutation and check details those without EGFR mutation (Figure 3). Patients with mutation had a median PFS of 8.8 months v 2.1 months for patients without EGFR mutation (P = 0.024). Evaluation of OS was available for no more than 50% deaths (85/194) at the last follow-up. Figure 3 Progression-free survival curves according to epidermal growth factor receptor mutational
status (A), phosphorylated tyrosine (pTyr) 1068 expression (B), pTyr1173 expression (C). pTyr1068 expression Of 205 assessable patients, 164 (80.0%) had EGFR phosphorylated at Tyr1068. The proportion of patients with pTyr1068 expression was similar across different demographic characteristics (Table 1). Among 194 patients receiving EGFR TKIs, there was a significant difference in ORR or DCR between pTyr1068 expression positive and negative Rho patients; ORR 39.5% (58/154) vs. 5.1% (2/40) P < 0.001, DCR 78.2% (115/154) vs. 41.0% (16/40) P < 0.001(Table 1). Patients with pTyr1068 expression had a prolonged PFS of TKIs treatment compared with those with unphosphorylated Tyr1068 (7.0 months vs. 1.2 months, P < 0.001, Figure 3). A logistic model further confirmed the significant correlation between pTyr1068 and response (OR 0.24, 95% CI 0.16 to 0.37, P < 0.001). The potential role of pTyr1068 expression in predicting clinical outcomes of EGFR-TKIs therapy in patients without EGFR mutation was investigated. The results were encouraging because of the conspicuous positive correlation with a better outcome from EGFR-TKIs therapy among patients with wild-type EGFR.